Abstract Details

Title Respiratory Comorbidities in Patients With Parkinson’s Disease

Topic Movement Disorders

Presentation(s) P13 - Poster Session 13 (8:00 AM-9:00 AM)

Poster/Presentation
Number 5-008

Background PD is a chronic neurodegenerative disease with widespread, debilitating effects. Respiratory disorders can occur in some patients with PD and may contribute to morbidity and mortality, which in turn may affect treatment selection for PD.

Objective

Evaluate the frequency of respiratory comorbidities in a cohort of patients with Parkinson’s disease (PD).

Design/Methods This was a longitudinal claims data analysis of the IQVIA PharMetrics® Plus database (closed, adjudicated medical and pharmacy claims in the United States). The analysis cohort included patients with continuous medical and pharmacy benefits from 2016 to 2018 with ≥1 diagnosis of PD (International Classification of Diseases, Tenth Revision [ICD-10], Clinical Modification code G20) with record types of management, surgery, facility, or pharmacy, and ≥1 pharmacy claim for carbidopa/levodopa ± entacapone. After cohort selection, the frequencies of mild and severe respiratory comorbidities were evaluated based on ICD-10 and clinical expert categorizations, and then were further categorized as acute or chronic.

Results

Among 8300 patients, the median age was 65 years and 64% were men. The frequency of any respiratory comorbidity was 49%. Any chronic respiratory comorbidity occurred in 19% of patients, with the most common (>1%) being asthma, chronic obstructive pulmonary disease, and snoring. The frequency of any acute respiratory comorbidity was 43%, with the most common (>5%) being cough, acute bronchitis, shortness of breath, pneumonia, and dyspnea (unspecified). Of these 8300 patients, 15% had chronic, severe respiratory comorbidities and 5% had chronic, mild respiratory comorbidities. Acute, severe respiratory comorbidities and acute, mild respiratory comorbidities occurred in 24% and 35% of patients, respectively.

Conclusions In this analysis of patients with PD, chronic and acute respiratory comorbidities were common, included a broad array of conditions, and when combined, were severe in over 30% of patients.

Authors/Disclosures
Andrew Thach, PhD (Sunovion Pharmaceuticals Inc.) PRESENTER	Dr. Thach has received personal compensation for serving as an employee of Sunovion Pharmaceuticals Inc.
	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
Eric Pappert	Eric Pappert has received personal compensation for serving as an employee of Sunovion Pharmaceuticals Inc..
Pinky Agarwal, MD, FAAN (Evergreen Health)	Dr. Agarwal has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Supernus. Dr. Agarwal has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Acadia Pharmaceuticals Inc. Dr. Agarwal has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Amneal. Dr. Agarwal has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Neurocrine. Dr. Agarwal has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Regenx Bio . Dr. Agarwal has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Cerevel Therapeutics. Dr. Agarwal has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Mitsubishi Tanabe Pharma. Dr. Agarwal has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Avion Pharma. Dr. Agarwal has received personal compensation in the range of $500-$4,999 for serving as a Consultant for AbbVie. Dr. Agarwal has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Acadia. Dr. Agarwal has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Supernus. Dr. Agarwal has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Kyowa Kirin. Dr. Agarwal has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Acorda. Dr. Agarwal has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Amneal. Dr. Agarwal has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for AbbVie. An immediate family member of Dr. Agarwal has stock in ACTINIUM PHARMACEUTICALS INC. An immediate family member of Dr. Agarwal has stock in ALDEYRA THERAPEUTICS INC. An immediate family member of Dr. Agarwal has stock in Aquestive Therapeutics. An immediate family member of Dr. Agarwal has stock in Corcept Therapeutics. An immediate family member of Dr. Agarwal has stock in Catalyst Pharmaceuticals. An immediate family member of Dr. Agarwal has stock in Curis Inc. An immediate family member of Dr. Agarwal has stock in Citius Pharmaceuticals. An immediate family member of Dr. Agarwal has stock in Fortress Biotech. An immediate family member of Dr. Agarwal has stock in Gevo Inc. An immediate family member of Dr. Agarwal has stock in G1 Therapeutics. An immediate family member of Dr. Agarwal has stock in Marinus Pharnmaceuticals. An immediate family member of Dr. Agarwal has stock in OVID Therapeutics. An immediate family member of Dr. Agarwal has stock in Pieris Pharmaceuticals. An immediate family member of Dr. Agarwal has stock in TG Therapeutics. An immediate family member of Dr. Agarwal has stock in ATYR PHARMA INC . An immediate family member of Dr. Agarwal has stock in ASSERTIO HOLDINGS INC . An immediate family member of Dr. Agarwal has stock in BLUEBIRD BIO INC . An immediate family member of Dr. Agarwal has stock in CORVUS PHARMACEUTICALS INC . An immediate family member of Dr. Agarwal has stock in GALECTO INC . An immediate family member of Dr. Agarwal has stock in GLYCOMIMETICS INC. An immediate family member of Dr. Agarwal has stock in Zevra Therapeutics. An immediate family member of Dr. Agarwal has stock in LAVA THERAPEUTICS . An immediate family member of Dr. Agarwal has stock in MEREO BIOPHARMA GROUP PLC. An immediate family member of Dr. Agarwal has stock in OVID THERAPEUTICS INC . An immediate family member of Dr. Agarwal has stock in PHASEBIO PHARMACEUTICALS INC. An immediate family member of Dr. Agarwal has stock in PROTALIX BIOTHERAPEUTICS INC. An immediate family member of Dr. Agarwal has stock in TERNS PHARMACEUTICALS INC. An immediate family member of Dr. Agarwal has stock in VIKING THERAPEUTICS INC. Dr. Agarwal has stock in WAVE LIFE SCIENCES LTD. An immediate family member of Dr. Agarwal has stock in Puma Biotech. An immediate family member of Dr. Agarwal has stock in Xeris Biopharma. An immediate family member of Dr. Agarwal has stock in Tonix Pharma. An immediate family member of Dr. Agarwal has stock in Spruce Biosciences. An immediate family member of Dr. Agarwal has stock in Cassava Sciences. An immediate family member of Dr. Agarwal has stock in ProQr Therapeutics. An immediate family member of Dr. Agarwal has stock in Mind Medicine. An immediate family member of Dr. Agarwal has stock in Lyra Therapeutics. An immediate family member of Dr. Agarwal has stock in Larimer Therapeutics. An immediate family member of Dr. Agarwal has stock in Lantern Pharma. An immediate family member of Dr. Agarwal has stock in Cue Biopharma. An immediate family member of Dr. Agarwal has stock in Caribou Biosciences. An immediate family member of Dr. Agarwal has stock in Capricor Therapeutics. An immediate family member of Dr. Agarwal has stock in Black Diamond Therapeutics. An immediate family member of Dr. Agarwal has stock in Applied Therapeutics. An immediate family member of Dr. Agarwal has stock in Amylyx Pharma. An immediate family member of Dr. Agarwal has stock in Palisade Bio. An immediate family member of Dr. Agarwal has stock in Passage Bio. An immediate family member of Dr. Agarwal has stock in Sutro Biopharma. An immediate family member of Dr. Agarwal has stock in Karyopharma. An immediate family member of Dr. Agarwal has stock in Inozyme Pharma. An immediate family member of Dr. Agarwal has stock in Oncolytic Biotech. An immediate family member of Dr. Agarwal has stock in Pyxis Oncology. An immediate family member of Dr. Agarwal has stock in Vistagen Therapeutics. An immediate family member of Dr. Agarwal has stock in Tscan Therapeutics. The institution of Dr. Agarwal has received research support from Biogen . The institution of Dr. Agarwal has received research support from CHDI Foundation. The institution of Dr. Agarwal has received research support from Eli Lilly. The institution of Dr. Agarwal has received research support from MJ Fox. The institution of Dr. Agarwal has received research support from Roche . The institution of Dr. Agarwal has received research support from Supernus. The institution of Dr. Agarwal has received research support from Nova Nordisc. The institution of Dr. Agarwal has received research support from Sun Pharma. The institution of Dr. Agarwal has received research support from Inhibikase.